| Literature DB >> 32425197 |
Toshiki Kuno1, Mai Takahashi2, Reiichiro Obata2, Tetsuro Maeda2.
Abstract
Using Mt. Sinai (New York City) EMR health system data, we retrospectively analyzed a cohort of 8438 COVID-19 patients seen between March 1 and April 22, 2020. Risk of intubation and of death rose as a function of increasing age and as a function of greater cardiovascular comorbidity. Combining age and specific comorbidity markers showed patterns suggesting that cardiovascular comorbidities increased relative risks for adverse outcomes most substantially in the younger subjects with progressively diminishing relative effects at older ages.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32425197 PMCID: PMC7227573 DOI: 10.1016/j.ahj.2020.05.005
Source DB: PubMed Journal: Am Heart J ISSN: 0002-8703 Impact factor: 4.749
Baseline characteristics of total cohort
| Number of patients: % (patient number) | |
|---|---|
| Age median [IQR] | 59 [43, 71] |
| Male | 53.9% (4544) |
| White | 25.8% (2179) |
| African American | 22.7% (1913) |
| Hypertension | 28.2% (2380) |
| Hyperlipidemia | 17.1% (1446) |
| Diabetes Mellitus | 19.0% (1606) |
| Coronary artery disease | 8.6% (723) |
| Peripheral artery disease | 8.1% (680) |
| Heart failure | 6.9% (584) |
| Chronic kidney disease | 12.4% (1049) |
| Dialysis | 1.7% (140) |
| Chronic obstructive lung disease | 2.4% (200) |
| Asthma | 8.7% (735) |
| Cancer | 7.0% (589) |
| Human Immunodeficiency Virus | 1.4% (121) |
Incidence of intubation and mortality for patients with cardio-vascular diseases for COVID-19 patients
| Intubation, % (event/total) | Death, % (event/total) | |||||
|---|---|---|---|---|---|---|
| Age Group | ||||||
| All ages | 11.6% (84/723) | 6.2% (475/7715) | 1.88 (1.52-2.35) | 30.2% (218/723) | 13.4% (1035/7715) | 2.24 (1.98-2.55) |
| ≤ 50 | 16.0% (4/25) | 3.2% (90/2851) | 5.07 (2.02-12.7) | 8.0% (2/25) | 2.0% (56/2851) | 4.07 (1.05-15.8) |
| 51-65 | 11.7% (21/179) | 7.1% (158/2237) | 1.66 (1.08-2.55) | 19.0% (34/179) | 10.4% (233/2237) | 1.82 (1.32-2.53) |
| 66-80 | 13.8% (45/327) | 9.4% (165/1751) | 1.46 (1.07-1.99) | 31.5% (103/327) | 21.8% (382/1751) | 1.44 (1.20-1.73) |
| ≥ 80 | 7.3% (14/192) | 7.1% (62/876) | 1.03 (0.59-1.80) | 41.1% (79/192) | 41.6% (364/876) | 0.99 (0.82-1.19) |
| All ages | 11.3% (77/680) | 6.2% (482/7758) | 1.82 (1.45-2.29) | 23.2% (158/680) | 14.1% (1095/7758) | 1.64 (1.42-1.91) |
| ≤ 50 | 7.5% (5/67) | 3.2% (89/2809) | 2.36 (0.99-5.61) | 7.5% (5/67) | 1.9% (53/2809) | 3.96 (1.63-9.58) |
| 51-65 | 13.0% (25/192) | 6.9% (154/2224) | 1.88 (1.27-2.79) | 15.6% (30/192) | 10.7% (237/2224) | 1.47 (1.03-2.08) |
| 66-80 | 13.3% (37/278) | 9.6% (173/1800) | 1.38 (0.99-1.93) | 25.9% (72/278) | 22.9% (413/1800) | 1.13 (0.91-1.40) |
| ≥ 80 | 7.0% (10/143) | 7.1% (66/925) | 0.98 (0.52-1.86) | 35.7% (51/143) | 42.4% (392/925) | 0.84 (0.67-1.06) |
| All ages | 14.6% (85/584) | 6.0% (474/7854) | 2.41 (1.94-2.99) | 34.2% (200/584) | 13.4% (1053/7854) | 2.55 (2.25-2.90) |
| ≤ 50 | 18.8% (9/48) | 3.0% (85/2828) | 6.24 (3.34-11.7) | 10.4% (5/48) | 1.8% (53/2828) | 5.56 (2.33-13.3) |
| 51-65 | 14.1% (20/142) | 7.0% (159/2274) | 2.01 (1.31-3.11) | 24.6% (35/142) | 10.2% (232/2274) | 2.42 (1.77-3.30) |
| 66-80 | 19.4% (45/232) | 8.9% (165/1846) | 2.17 (1.61-2.93) | 39.2% (91/232) | 21.3% (394/1846) | 1.84 (1.53-2.21) |
| ≥ 80 | 6.8% (11/162) | 7.2% (65/906) | 0.95 (0.51-1.75) | 42.6% (69/162) | 41.3% (374/906) | 1.03 (0.85-1.25) |
| All | 16.7% (387/2312) | 4.9% (146/3008) | 3.45 (2.87-4.14) | 41.3% (954/2312) | 8.1% (245/3008) | 5.07 (4.45-5.76) |
| ≤ 50 | 26.8% (40/149) | 5.4% (44/819) | 5.00 (3.38-7.39) | 23.4% (35/149) | 2.7% (22/819) | 8.74 (5.28-14.5) |
| 51-65 | 22.5% (126/561) | 4.4% (46/1050) | 5.13 (3.72-7.07) | 33.0% (185/561) | 6.7% (70/1050) | 4.95 (3.83-6.38) |
| 66-80 | 17.4% (157/902) | 5.5% (47/860) | 3.18 (2.33-4.35) | 42.5% (383/902) | 10.0% (86/860) | 4.25 (3.43-5.26) |
| ≥ 80 | 9.1% (64/700) | 3.2% (9/279) | 2.83 (1.43-5.62) | 50.1% (351/700) | 24.0% (67/279) | 2.09 (1.67-2.61) |
CAD, coronary artery disease; CI, Confidential interval; HF, heart failure; PAD, peripheral artery disease; RR, relative risk.